Eyal C. Attar - Sep 16, 2021 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SVP, Chief Medical Officer
Signature
/s/ Scott M. Coiante, attorney-in-fact
Stock symbol
APRE
Transactions as of
Sep 16, 2021
Transactions value $
-$74,730
Form type
4
Date filed
9/20/2021, 05:29 PM
Previous filing
Aug 27, 2021
Next filing
Mar 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Sale -$74.7K -16K -16.13% $4.68 83K Sep 16, 2021 Direct F1, F2
holding APRE Common Stock 172 Sep 16, 2021 By adult child F3
holding APRE Common Stock 159 Sep 16, 2021 By child F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.55 to $4.85 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.